1. Home
  2. FMST vs GRDX Comparison

FMST vs GRDX Comparison

Compare FMST & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foremost Lithium Resource & Technology Ltd.

FMST

Foremost Lithium Resource & Technology Ltd.

HOLD

Current Price

$1.35

Market Cap

30.5M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$2.90

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMST
GRDX
Founded
2005
N/A
Country
Canada
United Kingdom
Employees
2
2
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.5M
28.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FMST
GRDX
Price
$1.35
$2.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
187.9K
60.4K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$1.87
52 Week High
$4.57
$6.93

Technical Indicators

Market Signals
Indicator
FMST
GRDX
Relative Strength Index (RSI) 37.58 38.70
Support Level N/A $2.01
Resistance Level $1.96 $3.65
Average True Range (ATR) 0.18 0.39
MACD -0.05 -0.04
Stochastic Oscillator 6.58 25.29

Price Performance

Historical Comparison
FMST
GRDX

About FMST Foremost Lithium Resource & Technology Ltd.

Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: